Skip to main content
SpringerLink
Log in

Suicidal Ideation during Antidepressant Treatment

Do Genetic Predictors Exist?

  • Leading Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Suicidal thoughts during antidepressant treatment have recently been the focus of several candidate gene and genome-wide association studies. Although the clinical risk factors for such events are well known, unfortunately they do not help to predict who will have a suicidal event during antidepressant treatment and who will not. Pharmacogenomic studies have therefore attempted to use genetic variants to predict individual susceptibility to treatment-related suicidal ideation. In this perspective, several genetic predictors have been highlighted, the majority of which relate to common mechanisms of antidepressant action: genes involved in the neurotrophic and synaptic plasticity systems (CREB1, and BDNF and its receptor NTRK2), noradrenergic system (ADRA2A), glutamatergic system (GRIA3, GRIK2 and GDA), inflammatory and hypothalamic-pituitary-adrenal (HPA) axis systems (IL28RA and FKBP5) and in other brain functions (PAPLN, APOO, KCNIP4 and ELP3). Although some of these genes may be of interest in predicting antidepressant-induced suicidal ideation, they still need to be validated in better phenotypically designed samples. Several methodological factors are indeed responsible for the problems involved in implicating these findings in the causation of a clinically relevant phenotype. These include discrepancies between studies in defining phenotypes, with several different thresholds used to establish significant suicidal ideation; the use of scales not truly designed to measure suicidal ideation; and the paucity of true suicidal events (suicide attempts and/or completion) in pharmacogenomic studies.

In conclusion, pharmacogenomic studies are far from fulfilling their promise. There is a need for future pharmacogenetic studies targeting events that are clinically significant in order to find associated variants that will help clinicians to improve their treatment strategies. While awaiting these genetic predictors, clinicians need to bear in mind that all studies in this field support a beneficial effect of antidepressants on suicidal ideation. This should therefore encourage them to prescribe antidepressant medication even in patients with suicidal ideation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 332–9

    Article  PubMed  CAS  Google Scholar 

  2. US Food and Drug Administration. Clinical review: relationship between antidepressant drugs and suicidality in adults [online]. Available from URL: http://www.fda.gov/ [Accessed 2008 Apr 28]

  3. US Food and Drug Administration. Antidepressant use in children, adolescents and adults: medication guide for antidepressant drugs [online]. Available from URL: http://www.fda.gov/CDER/Drug/antidepressants/default.htm [Accessed 2008 Apr 28]

  4. Medicines and Healthcare products Regulatory Agency. Safety of selective serotonin reuptake inhibitor antide-pressants, 2004 [online]. Available from URL: http://www.mhra.gov.uk/index.htm [Accessed 2010 Dec 13]

  5. Friedman RA, Leon AC. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356(23): 2343–6

    Article  PubMed  CAS  Google Scholar 

  6. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164(9): 1356–63

    Article  PubMed  Google Scholar 

  7. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003; 28(5): 331–7

    PubMed  Google Scholar 

  8. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003; 72(2): 71–9

    Article  PubMed  Google Scholar 

  9. Machado-Vieira R, Salvadore G, Luckenbaugh DA, et al. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008; 69(6): 946–58

    Article  PubMed  Google Scholar 

  10. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292(3): 338–43

    Article  PubMed  CAS  Google Scholar 

  11. Nutt DJ. Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psycho-pharmacol 2003; 17(4): 355–64

    CAS  Google Scholar 

  12. Perlis RH, Beasley Jr CM, Wines Jr JD, et al. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom 2007; 76(1): 40–6

    Article  PubMed  Google Scholar 

  13. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993; 8(3): 186–212

    Article  PubMed  CAS  Google Scholar 

  14. Akiskal HS, Benazzi F, Perugi G, et al. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord 2005; 85(3): 245–58

    Article  PubMed  Google Scholar 

  15. Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses 2005; 65(1): 39–43

    Article  PubMed  CAS  Google Scholar 

  16. Harada T, Sakamoto K, Ishigooka J. Incidence and predictors of activation syndrome induced by antidepressants. Depress Anxiety 2008; 25(12): 1014–9

    Article  PubMed  CAS  Google Scholar 

  17. Culpepper L, Davidson JR, Dietrich AJ, et al. Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry 2004; 65(6): 742–9

    Article  PubMed  Google Scholar 

  18. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12(2): 192–214

    Article  PubMed  CAS  Google Scholar 

  19. Benazzi F. Suicidal ideation and depressive mixed states. Psychother Psychosom 2005; 74(1): 61–2

    Article  PubMed  Google Scholar 

  20. Baldassano CF, Truman CJ, Nierenberg A, et al. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996; 37(2): 122–4

    Article  PubMed  CAS  Google Scholar 

  21. Perroud N, Uher R, Marusic A, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. BMC Med 2009; 7: 60

    Article  PubMed  Google Scholar 

  22. Balazs J, Benazzi F, Rihmer Z, et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91(2-3): 133–8

    Article  PubMed  Google Scholar 

  23. Pokorny AD. Prediction of suicide in psychiatric patients: report of a prospective study. Arch Gen Psychiatry 1983; 40(3): 249–57

    Article  PubMed  CAS  Google Scholar 

  24. Goldstein RB, Black DW, Nasrallah A, et al. The prediction of suicide: sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Arch Gen Psychiatry 1991; 48(5): 418–22

    Article  PubMed  CAS  Google Scholar 

  25. van Egmond M, Diekstra RF. The predictability of suicidal behavior: the results of a meta-analysis of published studies. Crisis 1990; 11(2): 57–84

    PubMed  Google Scholar 

  26. Anderson RN. Deaths: leading causes for 1999. Natl Vital Stat Rep 2001;49(11): 1–87

    Google Scholar 

  27. Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet C Semin Med Genet 2005; 133C(1): 13–24

    Article  PubMed  Google Scholar 

  28. Fu Q, Heath AC, Bucholz KK, et al. A twin study of genetic and environmental influences on suicidality in men. Psychol Med 2002; 32(1): 11–24

    Article  PubMed  CAS  Google Scholar 

  29. Butler AW, Breen G, Tozzi F, et al. A genomewide linkage study on suicidality in major depressive disorder confirms evidence for linkage to 2p12. Am J Med Genet B Neuropsychiatr Genet 2010; 153B(8): 1465–73

    Article  PubMed  Google Scholar 

  30. Cui H, Supriyanto I, Asano M, et al. A common polymorphism in the 3′-UTR of the NOS1 gene was associated with completed suicides in Japanese male population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(6): 992–6

    Article  PubMed  CAS  Google Scholar 

  31. Wang Y, Zhang J, Liu B, et al. Genetic polymorphisms in the SCN8A gene are associated with suicidal behavior in psychiatric disorders in the Chinese population. World J Biol Psychiatry 2010; 11(8): 956–63

    Article  PubMed  Google Scholar 

  32. Nedic G, Nikolac M, Sviglin KN, et al. Association study of a functional catechol-O-methyltransferase (COMT) Val108/ 158Met polymorphism and suicide attempts in patients with alcohol dependence. Int J Neuropsychopharmacol 2011; 14(3): 377–88

    Article  PubMed  CAS  Google Scholar 

  33. Zalsman G, Patya M, Frisch A, et al. Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: a multi-center study. World J Biol Psychiatry 2011; 12(1): 33–41

    Article  PubMed  Google Scholar 

  34. Uher R, Perroud N. Probing the genome to understand suicide. Am J Psychiatry 2010; 167: 1425–7

    Article  PubMed  Google Scholar 

  35. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25(1): 119–42

    Article  PubMed  Google Scholar 

  36. Uher R, Farmer A, Maier W, et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008; 38(2): 289–300

    Article  PubMed  CAS  Google Scholar 

  37. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients: findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43(3): 215–29

    Article  PubMed  Google Scholar 

  38. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299(8): 901–13

    Article  PubMed  CAS  Google Scholar 

  39. Brent D, Melhem N, Turecki G. Pharmacogenomics of suicidal events. Pharmacogenomics 2010; 11(6): 793–807

    Article  PubMed  Google Scholar 

  40. Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64(6): 689–97

    Article  PubMed  CAS  Google Scholar 

  41. Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 2009; 19(9): 666–74

    Article  PubMed  CAS  Google Scholar 

  42. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164(10): 1530–8

    Article  PubMed  Google Scholar 

  43. Perroud N, Aitchison KJ, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 2009; 34(12): 2517–28

    Article  PubMed  CAS  Google Scholar 

  44. Menke A, Lucae S, Kloiber S, et al. Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry 2008; 165(7): 917–8

    Article  PubMed  Google Scholar 

  45. Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010; 167(2): 190–7

    Article  PubMed  Google Scholar 

  46. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord 2009; 117(1–2): 63–73

    Article  PubMed  Google Scholar 

  47. Perroud N, Uher R, Ng M, et al. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. Epub 2010 Sep 28

  48. Dwivedi Y, Rao JS, Rizavi HS, et al. Abnormal expression and functional characteristics of cyclic adenosine mono-phosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60(3): 273–82

    Article  PubMed  CAS  Google Scholar 

  49. Young LT, Bezchlibnyk YB, Chen B, et al. Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry 2004; 55(6): 570–7

    Article  PubMed  CAS  Google Scholar 

  50. Baud P, Courtet P, Perroud N, et al. Catechol-O-methyl-transferase polymorphism (COMT) in suicide attempters: a possible gender effect on anger traits. Am J Med Genet B Neuropsychiatr Genet 2007; 144B(8): 1042–7

    Article  PubMed  CAS  Google Scholar 

  51. Perlis RH, Purcell S, Fagerness J, et al. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry 2007; 62(5): 536–40

    Article  PubMed  CAS  Google Scholar 

  52. Palucha A, Pilc A. The involvement of glutamate in the pathophysiology of depression. Drug News Perspect 2005; 18(4): 262–8

    Article  PubMed  CAS  Google Scholar 

  53. Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60(8): 804–15

    Article  PubMed  CAS  Google Scholar 

  54. Altar CA, Whitehead RE, Chen R, et al. Effects of electro-convulsiveseizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54(7): 703–9

    Article  PubMed  CAS  Google Scholar 

  55. Coppell AL, Pei Q, Zetterstrom TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44(7): 903–10

    Article  PubMed  CAS  Google Scholar 

  56. Escriba PV, Ozaita A, Garcia-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004; 29(8): 1512–21

    Article  PubMed  CAS  Google Scholar 

  57. Wakeno M, Kato M, Okugawa G, et al. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol 2008; 28(5): 518–24

    Article  PubMed  CAS  Google Scholar 

  58. Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23(1): 11–25

    Article  PubMed  CAS  Google Scholar 

  59. Ising M, Depping AM, Siebertz A, et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 2008; 28(2): 389–98

    Article  PubMed  Google Scholar 

  60. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36(12): 1319–25

    Article  PubMed  CAS  Google Scholar 

  61. Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12(3): 365–77

    Article  PubMed  Google Scholar 

  62. Mann JJ, Currier D. A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch Suicide Res 2007; 11(1): 3–16

    Article  PubMed  Google Scholar 

  63. Scammell JG, Denny WB, Valentine DL, et al. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. Gen Comp Endocrinol 2001; 124(2): 152–65

    Article  PubMed  CAS  Google Scholar 

  64. Roy A, Gorodetsky E, Yuan Q, et al. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 2010; 35(8): 1674–83

    PubMed  CAS  Google Scholar 

  65. Janssen HL, Brouwer JT, van der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21(2): 241–3

    Article  PubMed  CAS  Google Scholar 

  66. Akum BF, Chen M, Gunderson SI, et al. Cypin regulates dendrite patterning in hippocampal neurons by promoting microtubule assembly. Nat Neurosci 2004; 7(2): 145–52

    Article  PubMed  CAS  Google Scholar 

  67. Feyissa AM, Chandran A, Stockmeier CA, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(1): 70–5

    Article  PubMed  CAS  Google Scholar 

  68. Guipponi M, Deutsch S, Kohler K, et al. Genetic and epigenetic analysis of SSAT gene dysregulation in suicidal behavior. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(6): 799–807

    Article  PubMed  CAS  Google Scholar 

  69. Brown G. A review of suicide assessment measures for intervention research with adults and older adults. Philadelphia (PA): University of Pennsylvania, 2002

    Google Scholar 

  70. Nock MK, Wedig MM, Janis IB, et al. Self-injurious thoughts and behaviors. In: Hunsley J, Mash EJ, editors. A guide to assessments that work. London: Oxford University Press, 2008: 158–78

    Google Scholar 

  71. Range LM, Knott EC. Twenty suicide assessment instruments: evaluation and recommendations. Death Stud 1997; 21(1): 25–58

    Article  PubMed  CAS  Google Scholar 

  72. Winters NC, Myers K, Proud L. Ten-year review of rating scales: III. Scales assessing suicidality, cognitive style, and self-esteem. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1150–81

    Google Scholar 

  73. Newport DJ, Levey LC, Pennell PB, et al. Suicidal ideation in pregnancy: assessment and clinical implications. Arch Womens Ment Health 2007; 10(5): 181–7

    Article  PubMed  CAS  Google Scholar 

  74. Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990–1992 to 2001–2003. JAMA 2005; 293(20): 2487–95

    Article  PubMed  CAS  Google Scholar 

  75. Suicidal behavior and psychotropic medication: accepted as a consensus statement by the ACNP Council, March 2, 1992. Neuropsychopharmacology 1993; 8 (2): 177-83

    Google Scholar 

  76. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development. A consensus statement. J Clin Psychiatry 2010; 71(8): e1–21

    Article  PubMed  Google Scholar 

  77. Meyer RE, Salzman C, Youngstrom EA, et al. Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development. A brief report. J Clin Psychiatry 2010; 71(8): 1040–6

    Google Scholar 

  78. Price AL, Kryukov GV, de Bakker PI, et al. Pooled association tests for rare variants in exon-resequencing studies. Am J Hum Genet 2010; 86(6): 832–8

    Article  PubMed  Google Scholar 

  79. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001; 69(1): 124–37

    Article  PubMed  CAS  Google Scholar 

  80. Frazer KA, Murray SS, Schork NJ, et al. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009; 10(4): 241–51

    Article  PubMed  CAS  Google Scholar 

  81. Iyengar SK, Elston RC. The genetic basis of complex traits: rare variants or “common gene, common disease”? Methods Mol Biol 2007; 376: 71–84

    Article  PubMed  CAS  Google Scholar 

  82. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008; 83(3): 311–21

    Article  PubMed  CAS  Google Scholar 

  83. Smith DJ, Lusis AJ. The allelic structure of common disease. Hum Mol Genet 2002; 11(20): 2455–61

    Article  PubMed  CAS  Google Scholar 

  84. Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010; 167(5): 509–27

    Article  PubMed  Google Scholar 

  85. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003; 100(24): 14293–6

    Article  PubMed  CAS  Google Scholar 

  86. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64(4): 341–57

    Article  PubMed  CAS  Google Scholar 

  87. Karege F, Vaudan G, Schwald M, et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136(1-2): 29–37

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist with preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University Hospitals of Geneva, Hôpital de Belle-Idée, Chemin du Petit-Bel-Air 2, 1225, Chêne-Bourg, Geneva, Switzerland

    Nader Perroud

Authors
  1. Nader Perroud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nader Perroud.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perroud, N. Suicidal Ideation during Antidepressant Treatment. CNS Drugs 25, 459–471 (2011). https://doi.org/10.2165/11589420-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589420-000000000-00000

Keywords

Search

Navigation